Considering that VS-1 can enhance the endothelial barrier function and inhibit angiogenesis in a variety of in vitro and in vivo assays in the 0.2-5 nM range [14, 16] it is possible that this fragment contributes, together with full-length CgA, to reduce CLL cell trafficking and organ infiltration in patients. Here, CGA is linked to B-cell chronic lymphocytic leukemia.